Skip to main content
. 2024 Apr 15;14(7):2656–2674. doi: 10.7150/thno.91456

Figure 3.

Figure 3

sdAb20 can specifically recognize AXL-expressing cells in the human THP-1 AML xenograft mouse model. (A) Schematic overview of an optimized protocol to investigate the biodistribution profile of sdAb20. 21-24 days post tumor-inoculation, mice will first receive a pre-determined dose of unlabeled, cold sdAb20-Fc, after which they are injected with radiolabeled (99mTc) sdAb20 after 0-72 h. One hour later, mice will undergo SPECT/CT imaging and ex vivo biodistribution through organ collection. Figure created with BioRender.com. (B) The ex vivo biodistribution profile of 99mTc-R3B23, 99mTc-sdAb20 alone and 99mTc-sdAb20 after pre-treatment with sdAb20-Fc for 24 h. Results are presented as mean %IA/g ± SD. (C) Heatmap of accumulation patterns of 99mTc-sdAb20 in various organs at different timepoints upon pre-treatment with sdAb20-Fc. The colour key represents the mean value of tracer accumulation in organs (%IA/g, n=3 for each group, n=5 for 24 h group). (D) Reconstructed SPECT/CT images of THP-1 xenograft mice showing maximum intensity projection and transversal planes. One reconstructed image representing three individual mice. White dashed circles indicate THP-1 tumors. (E) Differences in lung, liver, spleen, bone and (F) tumor, relative to blood uptake. (G) Uptake of 111In-labeled sdAb20-Fc in lung, liver, spleen, bone and (H) tumor at different timepoints. Data were represented as organ-to-blood ratio. p ≤ 0.05 (*) and p ≤ 0.0001 (****) were considered statistically significant. IA = injected activity, ID/cc = injected dose per cubic centimeter.